The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum is a translational science meeting focusing on scientific discoveries made in multiple sclerosis (MS) to advance the understanding of research and clinical care of patients with MS.
Carrie Hersh, DO, MSc: Addressing Progressive Disease in MSMarch 7th 2020
The assistant professor of neurology at the Lerner College of Medicine and neurologist at Luo Ruvo Center for Brain Health, both of Cleveland Clinic, spoke to the importance of preventing progression in MS and treating the non-inflammatory aspects of the disease.
Augusto Miravalle, MD: How Cladribine Sets Itself Apart in MSMarch 6th 2020
The associate professor in the department of neurology at the University of Colorado and neurologist at Advanced Neurology of Colorado discussed the advantages of cladribine and details of the ongoing CLICK-MS study.
Pascal Sati, PhD: Validating the Central Vein Sign in Multiple Sclerosis DiagnosisApril 16th 2019
The senior preclinical and clinical imaging scientist at the National Institute of Neurological Disorders and Stroke spoke about the potential of the central vein sign to help improve the time to an accurate diagnosis in MS.
Pascal Sati, PhD: Challenges in Imaging for Multiple SclerosisApril 8th 2019
The senior preclinical and clinical imaging scientist at the National Institute of Neurological Disorders and Stroke gave a presentation on a volumetric segmented echo-planar-imaging (3D-EPI) sequence, which could be used to detect novel biomarkers such as the central vein sign rapidly.
Rhonda Voskuhl, MD: A Bedside to Bench to Bedside Approach in MSApril 2nd 2019
The Professor in UCLA's Department of Neurology and Director of the UCLA MS Program stressed the importance of basing research on clinical observations, understanding them in the lab, then designing novel clincal trials.
John DeLuca, PhD: Ozanimod Resulted in Improved Cognitive Processing Speed in Relapsing MSMarch 30th 2019
The Senior Vice President for Research and Training at Kessler Foundation discussed the results of the SUNBEAM trial, which indicated that ozanimod resulted in sustained improvement in cognitive processing speed, supporting its efficacy in relapsing MS.
Marjan Gharagozloo, PhD: The Future of Multiple Sclerosis ResearchMarch 29th 2019
The immunology expert from the University of Sherbrooke shared her insight about where she sees the future of MS research headed, and the need to focus attention on the body’s innate immune response.
Mark Freedman, MD: Early Intervention With Interferon Beta-1b for Patients Presenting With CISMarch 28th 2019
The director of the multiple sclerosis research unit at Ottawa Hospital spoke about the results of BENEFIT 15 that support early intervention of interferon beta-1b treatment at or shortly after CIS.
Lisa Eunyoung Lee, MS, BSc: Myelin Water Imaging in the Spinal CordMarch 26th 2019
The research assistant at the University of British Columbia-Vancouver detailed the success of myelin water imaging in the spinal cords of both healthy controls and patients with multiple sclerosis.
Stephen Krieger, MD: Risk Mitigation in Multiple SclerosisMarch 25th 2019
The multiple sclerosis specialist at the Corinne Goldsmith Dickinson Center for MS at Mount Sinai spoke about risk mitigation in patients with MS and why it's important to choose medicines in an effective way.
Mark Freedman, MD: Precision Medicine in Multiple SclerosisMarch 24th 2019
The director of the multiple sclerosis research unit at Ottawa Hospital spoke about the need for clinicians to select the right patient for the right treatment in the MS clinic.
Increases in Myelin Water Fraction Detected in Patients Who Started Treatment With Ocrelizumab Or Switched to Ocrelizumab After IFNMarch 23rd 2019
The Global Head of Neuroimmunology at Genentech discussed the results of a substudy that found that the use of advanced imaging metrics in MS clinical trials may provide specific information about tissue damage and potential repair.
David Leppert, MD: Building a Foundation for Neurofilament LightMarch 22nd 2019
The therapeutic head of neuroinflammation and pain at Novartis spoke about his desire to work to a point where physicians can use NfL to monitor disease activity, make therapeutic decisions, and give perspective to patients.
Antje Bischof, MD, on Cervical Cord Tissue Loss As a Strong Indicator of Conversion to SPMSMarch 21st 2019
The postdoctoral scholar at the University of California, San Francisco, spoke about a prognostic marker that can be used to study the role of genetic, epidemiologic and immune variables on MS, and to measure the long-term impact of treatment in clinical trials.
Antje Bischof, MD: Accelerated Cord Atrophy Precedes Conversion to SPMS in RRMSMarch 19th 2019
The Postdoctoral Scholar at the University of California San Francisco spoke about a longitudinal study that evaluated the utility of spinal cord atrophy measured from brain scans as a surrogate marker for impending conversion to secondary progressive MS.